IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

DANESI, ROMANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 13.816
NA - Nord America 5.799
EU - Europa 4.483
SA - Sud America 1.716
AF - Africa 169
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 3
Totale 26.014
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.516
SG - Singapore 4.875
CN - Cina 4.394
BR - Brasile 1.380
HK - Hong Kong 1.351
VN - Vietnam 1.023
DE - Germania 1.017
IT - Italia 929
RU - Federazione Russa 851
BD - Bangladesh 670
IN - India 663
FR - Francia 480
GB - Regno Unito 354
NL - Olanda 336
KR - Corea 242
CA - Canada 129
AR - Argentina 123
FI - Finlandia 116
ID - Indonesia 110
JP - Giappone 101
SE - Svezia 94
MX - Messico 75
IE - Irlanda 73
TR - Turchia 65
EC - Ecuador 61
IQ - Iraq 57
ES - Italia 55
ZA - Sudafrica 50
CO - Colombia 44
PL - Polonia 35
PK - Pakistan 32
CI - Costa d'Avorio 30
CL - Cile 30
VE - Venezuela 28
UA - Ucraina 26
AU - Australia 24
MY - Malesia 24
PY - Paraguay 21
SA - Arabia Saudita 21
MA - Marocco 20
PH - Filippine 20
TH - Thailandia 20
AT - Austria 18
EG - Egitto 18
IR - Iran 17
UZ - Uzbekistan 17
JO - Giordania 14
CR - Costa Rica 13
AE - Emirati Arabi Uniti 12
JM - Giamaica 12
PE - Perù 12
TW - Taiwan 12
IL - Israele 11
TN - Tunisia 11
UY - Uruguay 11
BE - Belgio 10
DZ - Algeria 9
HN - Honduras 9
KZ - Kazakistan 9
NP - Nepal 9
CH - Svizzera 8
GT - Guatemala 8
KE - Kenya 8
SV - El Salvador 8
BG - Bulgaria 7
PR - Porto Rico 7
RO - Romania 7
AZ - Azerbaigian 6
BO - Bolivia 6
DK - Danimarca 6
GR - Grecia 6
LU - Lussemburgo 6
NO - Norvegia 6
RS - Serbia 6
SN - Senegal 6
AL - Albania 5
DO - Repubblica Dominicana 5
GE - Georgia 5
LB - Libano 5
LT - Lituania 5
NI - Nicaragua 5
PA - Panama 5
QA - Qatar 5
CZ - Repubblica Ceca 4
EU - Europa 4
MD - Moldavia 4
NZ - Nuova Zelanda 4
OM - Oman 4
PS - Palestinian Territory 4
BH - Bahrain 3
BY - Bielorussia 3
ET - Etiopia 3
KG - Kirghizistan 3
KW - Kuwait 3
PT - Portogallo 3
SY - Repubblica araba siriana 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BS - Bahamas 2
HR - Croazia 2
Totale 25.983
Salva come PNG Salva come JPEG
Città #
Hefei 2.066
Singapore 1.797
San Jose 1.095
Hong Kong 897
Dallas 669
Ashburn 667
Frankfurt am Main 649
Bengaluru 543
Council Bluffs 469
Lauterbourg 382
Ho Chi Minh City 375
Los Angeles 308
Moscow 265
Buffalo 255
Hanover 236
Beijing 234
Hanoi 234
Southend 222
Milan 210
Seoul 210
Guangzhou 189
New York 176
Fairfield 138
Cangzhou 114
São Paulo 101
Seattle 89
Tianjin 88
Helsinki 79
Shenzhen 79
Rome 71
Dublin 70
Santa Clara 65
Chandler 63
Woodbridge 62
Cambridge 61
Shanghai 61
Princeton 53
Naples 50
Wilmington 49
Jakarta 48
Tokyo 46
Houston 44
Chicago 40
Da Nang 39
Rio de Janeiro 39
Munich 38
Haiphong 35
Atlanta 33
Abidjan 30
Belo Horizonte 27
Toronto 27
Nanjing 26
Orem 26
Brasília 25
Curitiba 25
Boardman 24
Chennai 24
Mumbai 24
Nuremberg 23
Phoenix 23
Ann Arbor 22
Campinas 22
Changsha 22
Des Moines 22
Guayaquil 21
Redwood City 21
Dhaka 20
Istanbul 20
Mexico City 20
Montreal 20
Porto Alegre 20
Quito 20
Turin 20
Columbus 19
Brooklyn 18
London 18
Salvador 18
Warsaw 18
Washington 18
Baghdad 17
Can Tho 17
Denver 17
Hải Dương 17
Madrid 17
Ninh Bình 17
Biên Hòa 16
Florence 16
Hangzhou 16
Newark 16
Amsterdam 15
Bologna 15
Cape Town 15
Kuala Lumpur 15
San Francisco 15
Boston 14
Goiânia 14
Johannesburg 14
Bắc Ninh 13
Lappeenranta 13
Tashkent 13
Totale 14.808
Salva come PNG Salva come JPEG
Nome #
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients 510
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 337
5 '-Nucleotidase (CN-II) emerges as a new predictive biomarker of response in the gemcitabine-cisplatin treatment of non-small cell lung cancer 298
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment 262
Lessons from the first ecancer symposium on angiogenesis in gastric cancer 251
Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare 245
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer 245
Key concepts and critical issues on epoetin and filgrastim biosimilars: a position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation 226
Phase Ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets 205
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 202
Understanding EGFR heterogeneity in lung cancer 191
Raccomandazioni per l’esecuzione di indagini molecolari su biopsia liquida in oncologia 191
Rechallenge for Patients with RAS and BRAF Wild-Type Metastatic Colorectal Cancer with Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 185
KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer 183
Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naive patients with advanced non-small-cell lung cancer 177
The HOCT1/ABCB1 polymorphisms don’t condition the cytogenetic and molecular response or tolerability to first-line nilotinib in chronic myeloid leukemia patients 177
Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer 175
Expression of gemcitabine and cisplatin-related genes according to histology and stage in non-small-cell lung cancer (NSCLC) 159
Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer 155
The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and Safety 146
Immunocytokines in cancer treatment: A systematic review 143
Epigenetic patterns, accelerated biological aging, and enhanced epigenetic drift detected 6 months following COVID-19 infection: insights from a genome-wide DNA methylation study 140
Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer : a pharmacogenetic approach 137
Suramin as an anticomplementary agent in xenotransplantation 133
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy 131
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors 124
Clinical efficacy of clofoctol in treating odontogenic infections 120
Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients 120
Imatinib administration in two patients with liver metastases from GIST and severe jaundice 119
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies 118
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 111
Targeting HER2 in breast cancer with brain metastases: A pharmacological point of view with special focus on the permeability of blood-brain barrier to targeted treatments 111
TGF-β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanoma 111
Ceramide analogs, process for their preparation and their use as antitumor agents 105
Refining sorafenib therapy : lessons from clinical practice 105
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper 104
Cost-Effectiveness of Treatment Optimisation with Biomarkers for Immunotherapy in Solid Tumours: A Systematic Review 103
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer 103
IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients 102
Opioid metabolism and drug-drug interaction in cancer 101
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs) 100
Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-α Biologics 99
Antimicrobial peptides: therapeutic potential for the treatment of Candida infections 98
A selective antimuscarinic agent: pirenzepine. Review of its pharmacologic and clinical properties 94
Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review 94
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group 94
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 93
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression 93
Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project 93
Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years 93
Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management 92
process for the preparation of ceramide analogs and their use as antitumor agents 89
Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof 87
Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions 85
Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data 84
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma 84
Effetti del la somministrazione cronica di Suramina sul testicolo ed epididimo di ratto.Indagine morfo-istochimica 83
Genetic determinants in the study of colorectal cancer 83
Pharmacogenetic determinants of anti-cancer drug activity and toxicity 81
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients 80
Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis 79
Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer 78
In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists 77
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide 77
Depression of the immune responsiveness in mice treated with thioacetamide after antigen exposure 73
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study 73
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 73
Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival 72
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study 72
Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells 71
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients 71
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs 71
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells 70
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer 70
The penetration of roxithromycin into human skin 70
Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer 69
Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples 69
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis 69
Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients 69
5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer 69
5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer 68
Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues 68
Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma 68
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel 66
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs 66
Effect of suramin on human prostate cancer cells in vitro 66
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed 65
Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC 65
Fructose-1,6-diphosphate reduces acute ECG changes due to doxorubicin in isolated rat heart 64
Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma 64
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 64
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo 64
Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma 64
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors 63
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 63
Characterization of the toxicity of distamycin derivatives on cancer cell lines and rat heart 63
The antiproliferative effect of suramin on the cancer cell line SW-13 is mediated by the inhibition of transforming growth factor beta 1 (TGF-beta 1) 63
Ultrastructural and biochemical evidence of apoptosis induced by a novel inhibitor of protein geranylgeranylation in human MIA PaCa-2 pancreatic cancer cells 63
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis 63
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer 62
Totale 11.394
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.584
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.584
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202163 0 0 0 0 0 0 0 0 0 0 37 26
2021/2022526 17 14 36 46 48 43 53 51 57 56 49 56
2022/2023382 38 25 24 33 47 76 16 24 39 10 33 17
2023/2024682 12 16 23 14 44 39 110 91 45 88 90 110
2024/20255.177 91 133 265 140 197 142 522 528 273 643 537 1.706
2025/202618.656 1.511 2.852 3.100 2.266 1.180 971 1.371 1.103 1.830 842 1.630 0
Totale 26.703